OA09819A - Utilisation de la riboflavine dans le taitement de maladies liées aux virus hiv de l'herpès de la rétinite pigmentaire et du paludisme - Google Patents

Utilisation de la riboflavine dans le taitement de maladies liées aux virus hiv de l'herpès de la rétinite pigmentaire et du paludisme

Info

Publication number
OA09819A
OA09819A OA60422A OA60422A OA09819A OA 09819 A OA09819 A OA 09819A OA 60422 A OA60422 A OA 60422A OA 60422 A OA60422 A OA 60422A OA 09819 A OA09819 A OA 09819A
Authority
OA
OAPI
Prior art keywords
riboflavin
malaria
treatment
diseases related
retinitis pigmentosa
Prior art date
Application number
OA60422A
Other languages
English (en)
Inventor
Berque Jean
Original Assignee
Berque Jean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berque Jean filed Critical Berque Jean
Publication of OA09819A publication Critical patent/OA09819A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA60422A 1991-04-02 1993-10-01 Utilisation de la riboflavine dans le taitement de maladies liées aux virus hiv de l'herpès de la rétinite pigmentaire et du paludisme OA09819A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9104218A FR2674753B1 (fr) 1991-04-02 1991-04-02 Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables.

Publications (1)

Publication Number Publication Date
OA09819A true OA09819A (fr) 1994-04-15

Family

ID=9411559

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60422A OA09819A (fr) 1991-04-02 1993-10-01 Utilisation de la riboflavine dans le taitement de maladies liées aux virus hiv de l'herpès de la rétinite pigmentaire et du paludisme

Country Status (7)

Country Link
EP (1) EP0578733A1 (fr)
JP (1) JPH06506212A (fr)
AU (1) AU1654092A (fr)
CA (1) CA2107078A1 (fr)
FR (1) FR2674753B1 (fr)
OA (1) OA09819A (fr)
WO (1) WO1992017173A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244270A (en) * 1991-09-13 1995-07-26 Eisai Co Ltd Injectable composition comprising riboflavin
DE69333575T2 (de) * 1992-05-28 2005-08-25 Centre For Molecular Biology And Medicine, Richmond Quinone-derivate zur verbesserung der zellulare bioenergie
FR2696319B1 (fr) * 1992-10-02 1994-12-30 Jean Berque Utilisation de produits biologiques atoxiques et principalement de la riboflavine dans la fabrication des préservatifs et des gants de protection médico-chirurgicaux.
GB9321558D0 (en) * 1993-10-19 1993-12-08 Radopath Ltd Anti-viral agents
GB2319474A (en) * 1993-10-19 1998-05-27 Radopath Ltd Anti-viral agents
JPH07188052A (ja) * 1993-12-27 1995-07-25 Sanwa Kagaku Kenkyusho Co Ltd インターフェロン用作用効果増強剤及び該増強剤とインターフェロンとを含有する抗ウイルス活性増強組成物
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US6277337B1 (en) 1998-07-21 2001-08-21 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US6258577B1 (en) 1998-07-21 2001-07-10 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US6268120B1 (en) 1999-10-19 2001-07-31 Gambro, Inc. Isoalloxazine derivatives to neutralize biological contaminants
US7985588B2 (en) 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
TW590780B (en) 2000-06-02 2004-06-11 Gambro Inc Additive solutions containing riboflavin
US7648699B2 (en) 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
US6548241B1 (en) 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
US7579325B2 (en) 2001-03-21 2009-08-25 Eisai R & D Management Co., Ltd. Drugs containing reduced of vitamin B2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2096712A1 (en) * 1970-06-29 1972-02-25 Giraux Georges Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders
GB1431841A (en) * 1973-01-15 1976-04-14 Evans S C Ophthalmic-nutritional preparations
DE2559569A1 (de) * 1975-10-22 1977-04-28 Josef Hofmann Fluessiges futtermittel fuer brieftauben
US4500524A (en) * 1982-09-15 1985-02-19 Trustees Of Boston University Tranquilizing and reducing or preventing seizures
JPS61275228A (ja) * 1985-03-14 1986-12-05 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド 治療用タンパク組成物中のビ−ルスの光動的不活性化
DE3542309A1 (de) * 1985-11-29 1987-06-04 Cardona Federico Dr Medizinisches antioxidativum
JPH05500963A (ja) * 1989-10-06 1993-02-25 ザ　ベス　イスラエル　ホスピタル　アソシエイション 新規な酸化脂肪蛋白質とその調合方法
AU6729290A (en) * 1989-11-09 1991-06-13 Schering-Plough Healthcare Products, Inc. Riboflavin as a tanning enhancer

Also Published As

Publication number Publication date
AU1654092A (en) 1992-11-02
WO1992017173A2 (fr) 1992-10-15
FR2674753B1 (fr) 1995-03-10
CA2107078A1 (fr) 1992-10-03
FR2674753A1 (fr) 1992-10-09
WO1992017173A3 (fr) 1993-01-07
JPH06506212A (ja) 1994-07-14
EP0578733A1 (fr) 1994-01-19

Similar Documents

Publication Publication Date Title
FI952302L (fi) Pyran-2-onit ja 5,6-dihydropyranonit, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa
FR2647808B1 (fr) Poxvirus recombinant et vaccin contre le virus de l'herpes contenant ce poxvirus
FI911574A7 (fi) Uusia HIV-proteiineja ja -peptidejä, jotka ovat käyttökelpoisia aidsin toteamisessa, ennaltaehkäisyssä ja hoidossa
BR9606769A (pt) Tablete e processos para tratamento de uma infecção de vírus do herpes em um humano e para preparação do tablete
DK0429987T3 (da) 5,11-Dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepiner og deres anvendelse til forebyggelse eller behandling af HIV-smitte
FI923357A0 (fi) Framstaellning av fettsyramediciner.
FR2643557B1 (fr) Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv
PL297849A1 (en) Vaccine against and method of treating the patients infectedwith hiv virus
ZA936592B (en) Nutrition for persons infected with human immunodeficiency virus
PT983271E (pt) Hemissulfato carbociclico nucleosidico e a sua utilizacao no tratamento de infeccoes virais
ES2081286T3 (es) Nucleosidos de pirimidina antivirus del sida.
EP0382551A3 (en) Prevention and treatment of herpes virus infections
FR2689398B1 (fr) Compositions destinées au traitement de l'infection et des maladies provoquées par le virus de l'hépatite B (HBV).
DE69028993D1 (de) Verwendung von kaffein bei der behandlung von herpes-simplex-virusinfektionen
MC2246A1 (fr) Utilisation de trinitrobenzenes ou d'acide carminique dans le traitement du cancer ou des maladies virales
FR2684552B1 (fr) Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
FR2709964B1 (fr) Compositions pharmaceutiques antivirales proposées dans le traitement du SIDA et de l'Herpès.
EP0294538A3 (en) Use of nigericin in the treatment of viral diseases
AU6736096A (en) 1(hetero)aryl-4-(condensed thiazol-2-ylalkyl)-piperazine derivatives, their preparation and their use in the treatment of 5-ht1a-receptor mediated disorders
IL97110A0 (en) Benzylphosphonic acid derivatives,compositions containing them and their use in treating viral diseases
DE3750248D1 (de) Zubereitung und Behandlung der Haut mit Human-Leukocyten-Interferon.
ZA9010337B (en) Fibroblast growth factor for use in the prevention and treatment of viral infections
EP0425840A3 (en) Use of methenamine in the treatment of viral diseases and malign neoplasies
AU5461590A (en) 2-imino-thiadiazoline-5-sulphonamides and their use in the treatment of glaucoma
AU2880495A (en) Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses